Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13938 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Anneli Enblom Larsson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. Hauptthemen laut MEDLINE: Polycythemia, Thrombocytosis, Polycythemia Vera, Thromboembolism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Region Norrbotten, Stroke Foundation of Northern Sweden.
Abstract (Originalsprache)
Introduction
The management to reduce risk of thromboembolic complications in polycythemia vera and essential thrombocythemia are well established, but for other conditions with elevated hemoglobin, hematocrit, or platelets there are no consensus regarding treatment and follow up.
Aims
To assess frequency of elevated blood values in patients with thromboembolic event, how many of these should be investigated further regarding myeloproliferative neoplasm and if the risk of recurrent event is depending on underlying condition.
Methods
Retrospective cohort study of 3931 adult patients in the county of Norrbotten, Sweden, with thromboembolism during 2017 and 2018.
Results
Of the 3931 patients, 1195 had either elevated Hb, HCT, or platelets fulfilling the 2016 revised WHO criteria for PV and ET, and out of these 411 should be evaluated regarding underlying myeloproliferative neoplasms. Unexplained thrombocytosis and secondary erythrocytosis were associated with the highest rate of recurrent event as well as the most inferior restricted mean survival time.
Conclusion
Elevated blood values are common in patients with thromboembolic event and the high risk of recurrent event and inferior restricted mean survival time in patients with unexplained thrombocytosis and secondary erythrocytosis implicates the importance of finding and managing the underlying condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
- NU Hospital Group, Uddevalla, Sweden.
- Department of Radiation Sciences, Umea University, Umea, Sweden.
ORCID-Profile: Anneli Enblom Larsson, Björn Andréasson, Henrik Holmberg, Anders Själander
Förderung
- Region Norrbotten
- Stroke Foundation of Northern Sweden
Zitieren
APA
Larsson, A. E., Andréasson, B., Holmberg, H., Liljeholm, M., & Själander, A. (2023). Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study. European Journal of Haematology. https://doi.org/10.1111/ejh.13938
Vancouver
Larsson AE, Andréasson B, Holmberg H, Liljeholm M, Själander A. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study. European Journal of Haematology. 2023. doi:10.1111/ejh.13938
BibTeX
@article{Larsson2023,
author = {Larsson, Anneli Enblom and Andréasson, Björn and Holmberg, Henrik and Liljeholm, Maria and Själander, Anders},
title = {Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13938}
}
EUVIMED